Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01562782 · ClinicalTrials.gov registry record · NA
Change of Fructose to Fat in South Asians
A NA study of Diabetes and Cardiovascular Disease, sponsored by The Rogosin Institute.
- Completed
- Registry status
- NA
- Development phase
- 39
- Enrollment target
- 2
- Study locations
NCT01562782: Completed NA study of Diabetes and Cardiovascular Disease, sponsored by The Rogosin Institute.
NCT01562782 is a NA study of Diabetes and Cardiovascular Disease that has completed, run by The Rogosin Institute. The registered enrollment target is 39 participants, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01562782, a NA study of Diabetes and Cardiovascular Disease, has completed, sponsored by The Rogosin Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 39 participants
- Enrollment target
- 2
- Study locations
Study Summary
The purpose of this study is to determine whether hepatic de novo lipogenesis (DNL) in response to the ingestion of a mixture of glucose and fructose is greater in South Asians compared to controls (Caucasians).
Primary Outcome
Fold change in plasma very low density lipoprotein (VLDL) triglyceride palmitate between South Asians and Caucasians from baseline to 4 hours after an oral challenge of fructose:glucose, 1:1.
Conditions Studied
Interventions
- OTHER Fructose + Glucose Beverage
Study Locations (2)
New York
- The Rogosin Institute - New York
- Weill Cornell Medical College Clinical and Translational Science Center (CTSC) - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2012-04-02 |
| Est. Completion | 2013-10-10 |
| Phase | NA |
What the finished NCT01562782 record still lists
NCT01562782 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (99% lower).
The record links to 4 conditions, with Diabetes appearing as the primary indexed condition, and to 1 intervention - of which Fructose + Glucose Beverage is the first listed.
NCT01562782 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT01562782 about?
NCT01562782 is a clinical study titled "Change of Fructose to Fat in South Asians". The purpose of this study is to determine whether hepatic de novo lipogenesis (DNL) in response to the ingestion of a mixture of glucose and fructose is greater in South Asians compared to controls (Caucasians).
What is the current status of trial NCT01562782?
This trial is currently completed. It is a NA study. The enrollment target is 39 participants. The study started on 2012-04-02. Estimated completion is 2013-10-10.
What conditions does trial NCT01562782 study?
This clinical trial studies the following conditions: Diabetes, Cardiovascular Disease, Dyslipidemia, Elevated Triglycerides.
What interventions are being tested in trial NCT01562782?
The interventions under investigation include: Fructose + Glucose Beverage (OTHER).
Who is sponsoring clinical trial NCT01562782?
This trial is sponsored by The Rogosin Institute, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01562782 being conducted?
This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01562782's enrollment target sits among peer trials
39 270th of 338 higher than 69 of 338 other Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Effect of 2-Week Continuous Glucose Monitoring on Glycemic Management in Patients New-to-Insulin on Hospital Discharge
RECRUITING · NA
-
Effects of Whole vs. Nonfat Milk Consumption on Body Composition in Children
RECRUITING · NA
-
Efficacy of Viome's Precision Nutrition Program Towards Reducing HbA1c
RECRUITING · NA
-
Targeting Metabolic Syndrome From the Emergency Department Through Mixed-Methods: Pilot Trial
RECRUITING · NA
-
Maturation of Arteriovenous Fistula With Automated Sonography Assessments Trial
RECRUITING · NA
-
Bringing Advocacy Via Digital Guide to the Emergency Department (Project BADGE)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI